GSK, Zantac
GSK knew about Zantac cancer risk, attorneys tell jury in first trial
U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a jury in Chicago that pharmaceutical companies GSK and Boehringer Ingelheim knew the product could cause cancer if it was not handled properly but failed to warn the public.
GSK, Boehringer Put Profits Over Safety, Zantac Jury Told
Drugmakers GSK Plc and Boehringer Ingelheim GmbH prioritized profits over consumer safety by hiding the cancer risks of their once-blockbuster heartburn drug Zantac, according to lawyers representing a Chicago woman in the first of thousands of such claims to go before a US jury.
Selling the call option generates an income of 2.72% in just over three months, equaling around 9.62% annualized. If GSK ...
Alpibectir was developed in a public-private collaboration between GSK, Pasteur Institute Lille, and the University of Lille, and is designed as a companion to ethionamide (Eto), which is an important ...
The British drugmaker’s remaining 4.2% stake in its consumer health arm Haleon also boosted its bottom line, following its ...
GSK Plc raised its profit forecast for the year as it predicts higher-than-expected sales from HIV, infectious diseases and ...
GSK raised its full-year profit forecast on Wednesday on strong demand for its common respiratory vaccine and specialty HIV ...
Even with the threat of a potential new competitor in the respiratory syncytial virus (RSV) vaccine race on the horizon, GSK ...
GSK’s total sales increased 10% in the first quarter of 2024 compared to the same period last year, thanks in large part to ...
Genomics plc and GSK announced a new collaboration to explore the potential for using polygenic risk scores (PRS) in clinical trials, to improve understanding of disease risk and patient selection, ...
It’s been a turbulent few days for GSK’s respiratory business: On Tuesday, the U.S. Federal Trade Commission (FTC) further cracked down on “junk patent listings,” including those related to a ...
Q1 2024 Earnings Call Transcript May 4, 2024 GSK plc isn’t one of the 30 most popular stocks among hedge funds at the end of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback